FluMist Home offers self-administered nasal flu vaccine in 34 states

AstraZeneca has launched FluMist Home, a nasal spray flu vaccine that can be self-administered at home, expanding access to a broader segment of the population. The program, offered in 34 states for the upcoming 2025-2026 flu season, allows eligible individuals aged 2 to 49 to order the vaccine online, complete a medical screening, and receive the spray by mail, with instructions and storage guidance included. A shipping and processing fee of 8.99 applies, though the vaccine is covered by most commercial insurance plans.

FluMist Home follows the same live attenuated intranasal formulation used in clinical settings. The process begins with an online medical questionnaire, after which a licensed health professional reviews eligibility. If approved, the nasal spray is shipped to the consumer’s home on a chosen date. Administration is performed by the individual or a caregiver, with guidance to place the sprayer tip into each nostril and depress the plunger in a single motion. The spray is to be disposed of properly once used, and users can expect mild side effects such as a runny nose or throat irritation. Protection typically develops about two weeks after vaccination.